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ABSTRACT
Survivin, which is highly expressed and promotes cell survival in diffuse 
malignant peritoneal mesothelioma (DMPM), exclusively relies on exportin 1 (XPO1/
CRM1) to be shuttled into the cytoplasm and perform its anti-apoptotic function. 
Here, we explored the efficacy of Selective Inhibitors of Nuclear Export (SINE), 
KPT-251, KPT-276 and the orally available, clinical stage KPT-330 (selinexor), in 
DMPM preclinical models. Exposure to SINE induced dose-dependent inhibition of 
cell growth, cell cycle arrest at G1-phase and caspase-dependent apoptosis, which 
were consequent to a decrease of XPO1/CRM1 protein levels and the concomitant 
nuclear accumulation of its cargo proteins p53 and CDKN1a. Cell exposure to SINE 
led to a time-dependent reduction of cytoplasmic survivin levels. In addition, after 
an initial accumulation, the nuclear protein abundance progressively decreased, as a 
consequence of an enhanced ubiquitination and proteasome-dependent degradation. 
SINE and the survivin inhibitor YM155 synergistically cooperated in reducing DMPM 
cell proliferation. Most importantly, orally administered SINE caused a significant anti-
tumor effect in subcutaneous and orthotopic DMPM xenografts without appreciable 
toxicity. Overall, we have demonstrated a marked efficacy of SINE in DMPM preclinical 
models that may relay on the interference with survivin intracellular distribution 
and function. Our study suggests SINE-mediated XPO1/CRM1 inhibition as a novel 
therapeutic option for DMPM.
INTRODUCTION
Diffuse malignant peritoneal mesothelioma 
(DMPM) is an uncommon and locally aggressive tumor 
that develops from mesothelial cells lining the peritoneal 
cavity, and accounts for approximately 25–30% of all 
mesotheliomas [1, 2]. The prognosis of DMPM is poor 
and treatment of DMPM patients by palliative surgery, 
systemic/intraperitoneal chemotherapy and abdominal 
irradiation showed to be ineffective with a median survival 
of about one year [2–4]. The advent of a loco-regional 
strategy that combines aggressive cytoreductive surgery 
(CRS) with hyperthermic intraperitoneal chemotherapy 
(HIPEC) [3,4] significantly improved median survival up 
to 40–92 months in selected series of patients, although 
approximately 40–60% of patients still experience 
recurrence [3–5]. For these patients, and for those who 
are not eligible to CRS+HIPEC, the prognosis remains 
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severe due to the lack of effective alternative treatment 
options, highlighting the need to develop new therapeutic 
strategies.
Previous work from our lab suggests that 
dysregulation of the apoptotic pathway may play a role 
in DMPM resistance to chemotherapy and that survivin 
and other Inhibitors of Apoptosis Protein (IAP) family 
members may represent new therapeutic targets [6]. 
Indeed, we found that RNAi-mediated survivin 
knockdown in DMPM cells enhanced both spontaneous 
and cytotoxic drug-induced apoptosis [6], thus supporting 
the notion that agents targeting survivin may provide 
new treatment approaches for this disease. Survivin is a 
structurally unique member of the IAP family and it is 
involved both in the control of cell division and inhibition 
of the apoptotic machinery [7]. Notably, sub-cellular 
compartmentalization of survivin plays an essential role in 
determining its bifunctional role [8]. Nuclear localization 
of survivin is mainly involved in spindle monitoring at 
mitosis, whereas cytoplasmic/mitochondrial survivin 
counteracts pro-apoptotic signals by preventing caspase-9 
and caspase-3 activation [8]. While the low molecular 
weight of survivin allows its passive diffusion from the 
cytoplasm to the nucleus, its export from the nucleus 
back to the cytoplasm requires an interaction between 
the exportin-1/chromosome maintenance protein 1 
(XPO1/CRM1) and the specific leucine-rich nuclear 
export signals (NES) within survivin. This interaction is 
accomplished via the RanGTP/GDP axis [8, 9]. XPO1/
CRM1 is a key member of the importin β superfamily 
of nuclear transport receptors that are involved in the 
nucleo-cytoplasmic active transport of over 200 proteins, 
including transcription factors, tumor suppressors, cell-
cycle regulators and proteins involved in programmed cell 
death [10, 11].
Recently, a novel class of oral bioavailable small-
molecule Selective Inhibitors of Nuclear Export (SINE) 
has been developed. These inhibitors bind specifically 
to the NES-binding groove of XPO1/CRM1 and prevent 
the interaction with its cargo proteins [12–14]. These 
compounds have demonstrated anti-tumor activity in a 
variety of experimental models of solid and hematologic 
malignancies both in vitro and in vivo [12, 13, 15–29]. 
Among those, selinexor (KPT-330) is the most advanced 
SINE with >500 hematologic and solid cancer patients 
treated to date in a number of Phase I/II clinical trials. 
(http://www.clinicaltrials.gov).
In the present study we investigated the therapeutic 
potential of three SINE, namely KPT-251, KPT-276 and 
selinexor, in patient-derived DMPM experimental models. 
Our results show that XPO1/CRM1 inhibition significantly 
impairs DMPM cells growth in vitro and in vivo, by 
inducing a marked apoptotic response. Furthermore, we 
provide evidence that SINE exert their pro-apoptotic effect 
by controlling the sub-cellular localization of survivin 
and subsequently modulating its expression through an 
ubiquitin/proteasome-dependent mechanism.
RESULTS
SINE impair DMPM cell growth
The effect of SINE on cell growth of two human 
DMPM cell lines (STO and MesoII, expressing wild-
type and mutant TP53, respectively) (Supplementary 
Table 1), was assessed by MTS assay following exposure 
to increasing concentrations of KPT-251, KPT-276 or 
selinexor. A dose- and time-dependent inhibition of cell 
growth was consistently observed in both cell lines after 
treatment with the different compounds (Figure 1A and 
Supplementary Figure S1A, B). However, while STO 
cells showed a higher sensitivity to selinexor compared 
to KPT-251 and KPT-276, with IC50 values of 0.07 ± 0.01, 
0.23 ± 0.05 and 0.24 ± 0.02 μmol/L respectively, 
MesoII cells showed a comparable sensitivity to all the 
compounds with IC50 values of 0.35 ± 0.09, 0.36 ± 0.04 
and 0.47 ± 0.04 μmol/L, respectively. In addition, at 
concentrations up to 10 μmol/L, SINE did not alter the 
growth of both normal human lung fibroblast (WI38) and 
adult human prostate (RWPE-1) cell lines (Figure 1A).
SINE promote cell cycle arrest and induce 
a caspase-dependent apoptotic cell death 
in DMPM cells
Since XPO1/CRM1 mediates nuclear export of 
several cell cycle regulatory proteins, including p53, 
cyclin B1, cyclin D1, cyclin-dependent kinase inhibitor 
1a (CDKN1a) and cyclin-dependent kinase inhibitor 1b 
(CDKN1b) [9, 11], we set to determine the effect of SINE 
on cell cycle progression. DMPM cells were exposed 
to KPT-251, KPT-276 or selinexor (at predetermined 
IC50 and IC80 of each cell line), and stained with propidium 
iodide at 24, 48 and 72 hours-post treatment. Flow 
cytometry profiles of nuclear DNA content revealed 
that 24-hour treatment of STO cells with SINE was 
sufficient to induce an accumulation of cells in G1 phase 
and a reduction in the percentage of cells in S and G2/M 
compartments (Figure 1B). G1 phase accumulation 
markedly increased at 48 hours and reached a maximum 
72 hours-post exposure to the highest doses of SINE (87.6 
± 3.7%, 90.4 ± 1.8% and 96.1 ± 3.3% for KPT-251, KPT-
276, and selinexor, respectively) (Figure 1B). Although to 
a lesser extent compared to STO cells, an increase in the 
percentage of cells in G1 phase was appreciable following 
72-hour exposure to the highest selinexor concentration in 
MesoII cells (Figure 1B).
To verify whether SINE-induced tumor cell 
growth inhibition was also dependent on the induction 
of an apoptotic cell death, we analyzed the presence of 
Annexin V+ cells 48 and 72 hours-post drug exposure by 
flow cytometry. While the apoptotic cell fraction was <10% 
in control cells at both time points, a marked dose- and 
time-dependent increase in the percentage of Annexin V+ 
cells was observed in the treated STO and MesoII cells 
Oncotarget13121www.impactjournals.com/oncotarget
(Table 1 and Supplementary Figure S2). In addition, a 
significant dose- and time-dependent increase in caspase-3 
catalytic activity, as determined in vitro by the hydrolysis of 
the specific fluorogenic substrate, was found after treatment 
with each compound (Figure 1C and Supplementary 
Figure S3). Specifically, in STO cells exposed for 
72 hours to KPT-251, KPT-276 and selinexor (IC80), the 
catalytic activity of caspase-3 was 7-, 6- and 11-fold 
higher, respectively, than that observed in control samples 
(Figure 1C and Supplementary Figure S3A). Similarly, a 
21-, 23- and 33-fold increase in caspase-3 catalytic activity 
was also observed in MesoII cells treated with KPT-251, 
KPT-276 and selinexor, respectively (Figure 1C and 
Supplementary Figure S3A). Notably, the inhibitory effect 
of SINE on cell growth was almost completely reverted 
when DMPM cells were pretreated with the pan-caspase 
inhibitor z-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk; 
Figure 1D and Supplementary Figure S3B) -which by 
itself failed to impair cell growth (Figure 1D)-, providing 
evidence that SINE induce a caspase-dependent apoptotic 
cell death in DMPM cells.
SINE modulate nuclear levels of XPO1/CRM1 
and its cargo proteins
To better understand the mechanism underlying 
SINE cytotoxic effect, we determined the levels of 
expression of XPO1/CRM1 and its cargo proteins p53 
and CDKN1a before and after treatment. Consistently with 
previous works in different tumor type models [13, 17, 19, 
21–23, 25], immunoblotting analysis revealed that nuclear 
XPO1/CRM1 expression progressively decreased after 
SINE treatment (Figure 2A and Supplementary Figure S4). 
In addition, the compounds induced nuclear accumulation 
of p53 as early as 4 hours-post treatment initiation in both 
cell lines, whereas CDKN1a nuclear accumulation was 
observed only in STO cells (Figure 2A and Supplementary 
Figure S4).
SINE interfere with the subcellular localization 
of survivin and induce its down-regulation 
through the ubiquitin/proteosome pathway
Survivin is a key anti-apoptotic protein and a 
cargo of XPO1/CRM1 [7–9]. Previous work has shown 
that its subcellular localization determines its function 
[8, 10]. Therefore, we first assessed the effect of SINE 
on the subcellular compartmentalization of survivin by 
Western blot and ELISA. Interestingly, SINE treatment 
(at IC50) induced nuclear accumulation of survivin 
concomitant with a time-dependent cytoplasmic reduction 
(Figure 2A, 2B and Supplementary Figure S5). Survivin 
nuclear accumulation was observed as early as 2 hours-post 
exposure to each compound and it reached a maximum 
8 hours-post treatment initiation. Strikingly, starting from 
12  hours-post treatment initiation, a progressive decrease 
in nuclear survivin protein abundance was observed 
(Figure 2A, 2B and Supplementary Figures S5 and S6), 
resulting in a significant and time-dependent reduction of 
total protein amount (Figure 2C, 2D).
It has been recently shown in triple-negative breast 
cancer (TNBC) cells that inhibition of XPO1/CRM1 by 
selinexor represses survivin transcription by inhibiting 
STAT3 acetylation [22]. We therefore assessed STAT3 
protein expression and acetylation in DMPM cells 
following selinexor treatment by Western blot (Figure 2C). 
However, no measurable effects on protein levels and 
acetylation status were observed. Our data suggest that the 
decrease of survivin protein abundance in DMPM cells is 
not related to post-translational modifications of its well-
known transcriptional activator. Such a hypothesis is also 
corroborated by the evidence that exposure of DMPM 
cells to selinexor did not affect survivin mRNA expression 
(Figure 2E).
Since it has been reported that the forced retention 
of survivin in the nucleus promotes its clearance by 
the ubiquitin-proteasome proteolytic pathway [30], 
we checked whether selinexor-mediated XPO1/CRM1 
inhibition might lead to the ubiquitination of survivin 
nuclear fraction. Western blot experiments indicated that 
exposure of DMPM cells to selinexor resulted in multiple 
ubiquitination of survivin, which increased its molecular 
weight up to 100 kDa (Figure 2F). These results suggest 
that in DMPM cells the reduction of survivin nuclear 
fraction by selinexor is ascribable at least in part to its 
proteasome-dependent degradation. Indeed, exposure of 
STO cells to the proteosome inhibitor Bortezomib partially 
restored nuclear survivin levels in selinexor treated cells 
(Figure 2B, 2D and Supplementary Figure S6).
SINE synergistically cooperate with YM155 to 
inhibit DMPM cell proliferation
The combined effects of SINE and the survivin 
inhibitor YM155 -found to induce a time-dependent 
survivin decrease at both mRNA and protein level 
(Supplementary Figure S7)- were investigated in 
DMPM cells. In combination experiments, cells were 
simultaneously exposed to increasing concentrations of 
SINE and YM155for short (72 hours) and long (10 days) 
time periods, and the cytotoxic activity was assessed 
by MTS assay. Under both treatment conditions, SINE 
effectively cooperated at all concentrations with YM155 to 
inhibit DMPM cell growth (Figure 3A and Supplementary 
Figure S8). In fact, when cells were treated with the drug 
combinations, the inhibition of cell proliferation was 
consistently greater than that expected by simple additivity 
of the effects of the individual drugs (Figure 3A and 
Supplementary Figure S8). Such a synergistic interaction 
was drug concentration-dependent, as indicated by the 
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Figure 1: SINE impair cell growth, promote cell cycle arrest, and induce apoptosis in DMPM cells. A. Cytotoxic activity 
of SINE in DMPM (STO and MesoII) and human normal (WI38 and RWPE-1) cell lines. Cells were cultured for 72 hours in the presence 
of increasing concentrations of SINE, and the cytotoxic activity was assessed by MTS assay. Data are expressed as mean values ±SD of 
at least three independent experiments. B. Flow-cytometric analysis of DMPM cells stained with propidium iodide at different intervals 
(24, 48, and 72 hours) after treatment with 0.01% DMSO (ctr) or SINE (IC50 and IC80, which were determined graphically from the dose-
response curves obtained after a 72-hour exposure of cells to SINE in the MTS assay). Data are reported as the percentage of cells in 
G1, S and G2/M phases and represent the mean values of three independent experiments; SDs were always within 5%. C. Assessment of 
caspase-3 catalytic activity at 48 and 72 hours after treatment with 0.01% DMSO (ctr) or selinexor (IC50 and IC80, which were determined 
graphically from the dose-response curves obtained after a 72-hour exposure of cells to the drug in the MTS assay). Data are expressed as 
relative fluorescence units and represent the mean values ±SD of at least three independent experiments. D. Cytotoxic effect of selinexor in 
DMPM cells after pre-incubation with z-VAD-fmk. Cells were cultured for 72 hours with selinexor (IC50 and IC80, which were determined 
graphically from the dose-response curves obtained after a 72-hour exposure of cells to SINE) in the presence/absence of z-VAD-fmk, 
and the cytotoxic activity was assessed by MTS assay. Data are expressed as percentage values of growth in treated cells compared with 
cells exposed to 0.01% DMSO (ctr), and represent mean values ±SD of at least three independent experiments.  ***P < 0.001, **P < 0.01, 
*P < 0.05.
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progressive decrease of combination index (CI) values 
(Figure 3A and Supplementary Figure S8). Moreover, 
caspase-3 catalytic activity was consistently and 
significantly higher in cells treated with the selinexor/
YM155 combination than in cells exposed to single agents 
(Figure 3B).
Oral SINE show anti-tumor activity in 
DMPM xenografts
We next examined the in vivo anti-tumor activity of 
oral administration of SINE in DMPM xenografts. In vivo 
activity of KPT-251, KPT-276 and selinexor was initially 
tested against early-stage subcutaneous STO xenografts in 
nude mice. A remarkable and superimposable anti-tumor 
effect was observed after treatment with the different 
agents (Figure 4A and Table 2), and a stabilization of 
tumor volume was appreciable up to 2 weeks post drug 
withdrawal (Figure 4A). Although to a lesser extent 
compared to early-stage tumors, the clinically available 
compound selinexor produced a significant tumor growth 
inhibition even in late-stage STO tumors (Figure 4A and 
Table 2). In addition, selinexor significantly inhibited the 
growth of both early- and late-stage subcutaneous MesoII 
tumors (Figure 4B and Table 2). Strikingly, in late-stage 
STO and MesoII tumors, the growth was dramatically 
slowed at the beginning of the treatment, and tumor 
volumes kept almost constant during the course of drug 
administration (Figure 4B).
Given the strong in vitro synergistic activity of the 
selinexor/YM155 combination, we explored whether 
this effect was also appreciable in vivo. However, results 
obtained in early-stage STO tumors revealed that YM155 
failed to appreciably improve the anti-tumor activity of 
selinexor (Supplementary Figure S9).
The anti-tumor activity of selinexor was further 
investigated in STO cells orthotopically xenotransplanted 
into SCID mice. Twenty-five days after cells i.p. 
injection (i.e., 24 hours after the last treatment), mice 
were euthanized and tumors were removed. At necropsy, 
control (vehicle-treated) mice showed a large tumor mass 
at the site of cell injection mainly invading the peritoneum 
wall, and widespread small nodules in the peritoneum and 
attached to the diaphragm, liver and bowel (Figure 4C), 
resulting in a tumor burden (average ± SD mg) of 328 ± 
69 mg (Figure 4D). In selinexor-treated animals, the size 
of the single residual tumor mass -which was adherent 
to the peritoneum, in the site of cell injection- was 
significantly reduced (88 ± 21 mg) compared to control 
mice (Figure 4D, 4E and Table 2). In addition, TUNEL and 
survivin immunohistochemical staining of tumor sections 
obtained from orthotopic xenografts revealed increased 
apoptosis and reduced survivin expression at both nuclear 
and cytoplasmic cellular compartments (Figure 4F) in 
selinexor-treated compared to control mice. These results 
were further corroborated by Western blot analysis 
performed on frozen tumor samples (Figure 4G).
SINE were well tolerated, with no toxic deaths 
and minimal weight loss (<5%). In addition, no gross 
pathology was observed at necropsy carried out at the end 
of each experiment.
Taken together our findings suggest that the reduced 
expression of the anti-apoptotic protein survivin is a major 
mechanism by which SINE exert their anti-tumor activity 
and provide a rationale basis for offering treatment of 
DMPM with SINE.
Table 1: Induction of apoptosis in DMPM cells treated with KPT-251, KPT-276 and selinexor
STO MesoII
Treatment 48 hours 72 hours 48 hours 72 hours
ctr 5.1 ± 0.7 3.3 ± 0.5 9.0 ± 2.1 3.2 ± 1.1
KPT-251 IC50 8.6 ± 1.7
* 18.6 ± 2.5** 14.5 ± 1.6** 22.1 ± 0.3***
IC80 14.5 ± 1.2
** 22.6 ± 0.9*** 22.2 ± 1.5*** 30.5 ± 0.8****
KPT-276 IC50 7.9 ± 0.4
* 17.0 ± 2.0** 19.6 ± 2.2*** 26.4 ± 4.5***
IC80 13.0 ± 1.2
** 25.6 ± 1.0*** 27.1 ± 1.1*** 45.5 ± 2.1****
selinexor IC50 11.3 ± 2.9
* 21.5 ± 2.8*** 22.3 ± 3.2*** 37.5 ± 1.1****
IC80 12.7 ± 1.3
* 28.9 ± 1.9*** 33.0 ± 2.0**** 61.7 ± 1.7****
Induction of apoptosis was evaluated by flow cytometry as the presence of Annexin V positive cells (i.e., Annexin V+/PI- 
plus Annexin V+/PI+ cells) after 48 and 72 hours of treatment with 0.01% DMSO (ctr) or SINE (IC50 and IC80, which were 
determined graphically from the dose-response curves obtained after a 72-hour exposure of cells to the different compounds 
in the MTS assay). Data represent mean values ±SD of at least three independent experiments. ****P < 0.0001, 
***P < 0.001, **P < 0.01, *P < 0.05.
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Figure 2: SINE inhibit XPO1/CRM1 functions, interfere with survivin subcellular distribution and promote its 
proteosome-dependent degradation. A. Representative western immunoblotting showing nuclear and cytosolic fractions of XPO1/
CRM1, p53, CDKN1a and survivin in DMPM cells exposed to selinexor (IC50). β-actin and TBP were used to confirm equal protein 
loading on the gel and to show the relative purity of the nuclear fractions. B. Quantification of nuclear and cytosolic survivin protein levels 
by ELISA assay in DMPM cells exposed to selinexor (IC50) alone or in the presence of subtoxic concentrations of Bortezomib. Data are 
reported as amount (pg) of survivin normalized to total (mg) protein, and represent the mean values ±SD of at least three independent 
experiments. C. Representative western immunoblotting showing the expression of survivin, STAT3 and Ac-STAT3 in DMPM cells 
exposed to selinexor (IC50). β-actin was used to confirm equal protein loading on the gel. D. Quantification of survivin protein levels by 
ELISA assay in DMPM cells exposed to selinexor alone (IC50) or in the presence of subtoxic concentrations of Bortezomib (1 nmol/L). 
Data are reported as the percentage of survivin expression in selinexor-treated cells compared with cells exposed to 0.01% DMSO (ctr), 
and represent the mean values ±SD of at least three independent experiments. E. Quantification of survivin mRNA expression levels by 
qRT-PCR in DMPM cells exposed to selinexor (IC50). Data are reported as log10-transformed relative quantity (RQ) in selinexor-treated 
cells with respect to cells exposed to 0.01% DMSO (ctr), and represent the mean values ±SD of at least three independent experiments. 
Dashed line: relative survivin mRNA expression level in the ctr. F. Representative IP experiment showing increased ubiquitination of 
nuclear survivin in STO cells exposed to selinexor (IC50) ***P < 0.001, **P < 0.01, *P < 0.05, vs ctr; °°°P < 0.001, °°P < 0.01, °P < 0.05, 
cells exposed to selinexor vs cells exposed to selinexor+Bortezomib.
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Figure 3: Synergistic cytotoxic effect of SINE/YM155 combinations. A. Cytotoxic effect of KPT-251 (up), KPT-276 (middle) 
and selinexor (down) in combination with YM155. DMPM cells were exposed to SINE and YM155 for 72 hours, and the cytotoxic 
effect was assessed by MTS assay. Black lines represent the expected additive effect of the combination, calculated as the product of the 
effects of the individual drugs, according to the method of Kern et al [46]. Data are expressed as percentage values of growth in treated 
cells compared to cells exposed to 0.01% DMSO (ctr), and represent mean values ±SD of at least three independent experiments. CI was 
calculated according to Chou and Talalay [45]. B. Assessment of caspase-3 catalytic activity at 72 hours after treatment with selinexor and 
YM155, alone and in combination. Data are expressed as relative fluorescence units and represent the mean values ±SD of at least three 
independent experiments. **P < 0.001, *P < 0.01, vs single treatments.
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Figure 4: Efficacy of oral SINE against DMPM xenografts. A. Tumor growth curves of STO cells subcutaneously injected 
into right flank of nude mice. Mice (eight mice/group) were randomly grouped to receive vehicle, KPT-251 (50 mg/kg, q3-4d × 8),  
KPT-276 (50 mg/kg, 5d/w × 3w) or selinexor (10 mg/kg, q3-4d × 8). The treatment started 4 (early-stage tumor; up) or 26 days (late-
stage tumor; down) after cell injection. The treatment duration is indicated by the gray bar. B. Tumor growth curves of MesoII fragments 
subcutaneously implanted into right flank of nude mice. Mice (eight mice/group) were randomly grouped to receive vehicle or selinexor 
(10 mg/kg, q3-4d × 8). The treatment started 4 (early-stage tumor; up) or 28 days (late-stage tumor; down) after tumor fragments implant. 
The treatment duration is indicated by the gray bar. C. Representative photograph showing the growth pattern of STO cells following 
xenotransplantation in the peritoneal cavity of SCID mice. Arrow indicates the tumor mass and widespread tumor nodes. D. Orthotopic 
tumor weight distribution. Mice (nine mice per group) were randomly grouped to receive vehicle or selinexor (10 mg/kg, q3-4d × 8). 
The treatment started the day after cells injection and stopped 25 days after cells injection (i.e. 24 hours after the last drug treatment). 
E. Photographs of tumors from five representative mice per experimental group reported in D. F. Representative hematoxylin-eosin 
(H/E), TUNEL and survivin staining performed in FFPE sections of tumors from the experimental groups reported in D. Images for one 
representative mouse per group are shown. Original magnification: x40. G. Western immunoblotting showing the survivin expression in 
tumors from four representative mice per experimental group reported in D.
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DISCUSSION
DMPM is inherently resistant to chemotherapy, 
which is considered a palliative treatment for patients 
who are not eligible for radical surgery. Currently, there is 
no standard systemic chemotherapy and no drug officially 
approved for the disease [2–4]. A limited knowledge on 
the dysregulated molecular pathways in DMPM, that could 
be specifically modulated to obtain a direct therapeutic 
effect or to increase the tumor sensitivity to conventional 
anticancer agents, also prevented the use of targeted 
therapeutic approaches in the clinical management of 
DMPM patients. These reasons underline the urgent need 
for new and more effective therapies for DMPM.
Based on the notion that mislocalization of proteins, 
which highly affect their functions, is a common feature in 
cancer [31], the regulation of protein trafficking between 
the nucleus and cytoplasm has been recently regarded as 
a novel control point for therapeutic interventions [32]. 
Clinical trials using leptomycin B, which specifically 
binds and block XPO1/CRM1 [33], proved to be too toxic 
for patients [34]. However, novel, rationally designed 
small molecules that form a slowly reversible covalent 
bond in the cargo-NES binding domain of XPO1/CRM1, 
i.e. SINE, (12–14) have been recently developed. In this 
study we demonstrated that SINE induce anti-proliferative 
and pro-apoptotic effects in DMPM cell lines and, 
most importantly, significantly inhibit the growth of 
subcutaneous and orthotopic DMPM xenografts at well-
tolerated doses.
XPO1/CRM1 has been reported to have an 
increased expression in several tumor types [12, 25, 
26, 35–40]. In this context, gene expression profiling 
analysis on clinical DMPM and normal peritoneum 
samples (unpublished data) showed significantly higher 
XPO1/CRM1 mRNA levels in tumors (Supplementary 
Figure S10). Interestingly, though six other members of 
the nuclear export protein family have been identified 
(XPO2-7), XPO1/CRM1 is the sole nuclear exporter 
for some of the major tumor suppressors (i.e., p53), cell 
cycle regulators (i.e., CDKN1a) and growth promoting 
proteins (i.e., survivin) [9–11]. TP53 is one of the most 
frequently mutated genes in human cancers [41]. In this 
context, it has been shown that XPO1/CRM1 is able to 
export not only wild-type p53 but also mutant proteins 
which carry mutations in regions other than NES [42]. 
Specifically, the p53 NES lies within a highly conserved 
region in the C-terminal tetramerization domain (which is 
between the first and second of three nuclear localization 
signals spanning amino acids 316–325, 369–375 and 
379–384 [43]), and only mutations of residues in this 
region prevent p53 XPO1/CRM1-mediated export [42]. 
In this study, we focused on two DMPM models, STO and 
MesoII, bearing wild-type and mutant p53, respectively. 
Notably, in both cell models, the p53 becomes trapped in 
the nucleus following SINE-mediated inhibition of XPO1/
CRM1, since p53 mutations in MesoII cells do not occur 
in the NES.
We previously reported that survivin -as well as 
other members of the IAP family- is largely overexpressed 
in clinical DMPM [6], possibly contributing to its inherent 
chemoresistance, and suggested that strategies aimed at 
down-regulating survivin may provide a novel approach 
for the treatment of DMPM. Indeed, we found that siRNA-
mediated survivin knockdown in DMPM cells significantly 
reduced their proliferative potential and enhanced both 
spontaneous and cisplatin- and doxorubicin-induced 
apoptosis. Based on this evidence highlighting a possible 
important function of survivin in sustaining DMPM cell 
growth, we explored the role of the anti-apoptotic protein 
as a determinant of SINE anticancer activity.
Exposure to single SINE compounds, KPT-251, 
KPT-276 or selinexor, induced a time- and dose-dependent 
inhibition of growth of the two DMPM cell lines without 
Table 2: Antitumor activity of SINE against DMPM xenografts
Cell model Site of inoculum Stage of tumors Drug Dose (mg/kg) Schedule TVI% (day)a
STO s.c. early KPT-251 50 q3-4d x8 84 (33)*
s.c. early KPT-276 50 5d/w x3w 84 (19)*
s.c. early selinexor 10 q3-4d x8 79 (33)*
s.c. late selinexor 10 q3-4d x8 54 (44)*
orthotopic early selinexor 10 q3-4d x8 73 (25)***
MesoII s.c. early selinexor 10 q3-4d x8 68 (28)**
s.c. late selinexor 10 q3-4d x8 62 (46)*
Abbreviation: s.c., subcutaneous model.
aTVI% represents the maximum tumor volume inhibition % in treated vs control mice. In parentheses, the day on which it 
was assessed.
***P < 0.0001, **P < 0.01, *P < 0.05 vs vehicle treated mice.
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affecting normal cell proliferation. Such a cell growth 
inhibition was preceded by a decline in nuclear XPO1/
CRM1 levels and an increase in nuclear accumulation of 
its cargo proteins p53 (in both cell lines) and CDKN1a 
(in STO cells only). These results were consistent with 
previous observations in cell lines from other human 
tumor types [12, 17, 20, 24–26, 28]. Here we show that 
survivin is an essential component in DMPM cell response 
to SINE-mediated XPO1/CRM1 inhibition. In fact, in 
both cell lines, exposure to SINE led to a time-dependent 
reduction of cytoplasmic survivin levels and, after an 
initial survivin nuclear accumulation, also to a progressive 
decrease in the nuclear protein abundance, through the 
ubiquitin-proteasomal degradation pathway, ultimately 
leading to the complete depletion of total survivin levels. 
Conversely to what was reported in TNBC cells, in 
which exposure to SINE repress survivin transcription by 
inhibiting CREB-binding mediated STAT3 acetylation and 
blocking STAT3 binding to the survivin promoter [22], in 
DMPM cell models SINE compounds failed to interfere 
with STAT3 acetylation status and to modulate survivin 
mRNA expression, suggesting that drug-induced effect on 
transcription could be cell-context dependent.
In both DMPM cell models, drug-induced reduction 
of cytoplasmic survivin levels correlated with the onset 
of caspase-dependent apoptosis. We further observed that 
SINE can be combined with other survivin inhibitors, such 
as the survivin suppressant YM155 -which is currently 
being tested in clinical trials (http://www.clinicaltrials 
.gov) [7]- to achieve enhanced in vitro growth inhibition 
in DMPM cells.
In vivo experiments with orally administered KPT-
251, KPT-276 or selinexor indicated that each compound 
was able to significantly reduce the growth of early stage 
subcutaneous STO xenografts. Interestingly, additional 
experiments carried out with selinexor, the first-in-class 
SINE currently being developed for clinical use in solid 
and hematologic malignancies (http://clinical trials.
gov), demonstrated that the compound was also able to 
inhibit the growth of late-stage subcutaneous STO and 
MesoII xenografts in nude mice. Most importantly, oral 
administration of selinexor to SCID mice reduced the 
growth of orthotopic STO xenografts, which properly 
recapitulate the dissemination pattern in the peritoneal 
cavity of human DMPM and, for this reason, represent 
a valuable model for investigating novel therapeutic 
approaches for the disease. Consistent with an important 
role of survivin as a determinant of anti-cancer activity of 
SINE compounds, a reduction of the protein expression 
was observed in tumor specimens obtained from selinexor 
treated mice.
Overall, our preclinical data corroborate previous 
evidence of an important anti-neoplastic activity of SINE 
compounds in experimental models of many human solid 
and hematologic malignancies [12, 13, 15–29] and form a 
solid foundation that could promote the clinical translation 
of SINE for the treatment of DMPM. In addition, survivin 
down-regulation appears as a main mechanism of SINE 
anti-cancer activity in DMPM experimental models, 
suggesting the anti-apoptotic protein as a possible 
biomarker for patient selection in the clinical setting. 
In this context, preliminary data of activity of selinexor 
from solid malignancy trials, together with the low 
toxicity profile of this class of compounds [44] and their 
synergistic effects in combination with other anticancer 
agents, further support the clinical development, also in 
combination regimens, of SINE against malignancies 
that are highly refractory to current chemotherapies, such 
as DMPM.
MATERIALS AND METHODS
Drugs
For in vitro studies, KPT-251, KPT-276, selinexor 
(provided by Karyopharm Therapeutics Inc.), and 
YM155 (purchased from Selleck Chemicals; #S1130) 
were initially dissolved in DMSO, stored at –20°C, and 
diluted in complete culture medium immediately before 
use. For in vivo studies, KPT-251, KPT-276 and selinexor 
were prepared as previously described [20]; YM155 was 
dissolved in sterile 0.9% saline solution.
Cell lines
Human DMPM cell lines (STO and MesoII) 
were established from surgical specimens of patients 
who underwent surgery at Fondazione IRCCS 
Istituto Nazionale dei Tumori of Milan, as previously 
described [6]. The normal human lung fibroblast (WI38) 
and the normal adult human prostate (RWPE-1) cell 
lines were obtained from the American Type Culture 
Collection (ATCC; #CCL-75 and #CRL-11609). Cells 
were maintained in the logarithmic growth phase as 
a monolayer in DMEM F12 (STO and MesoII) and 
DMEM (WI38) media (Lonza; #12-719F and #12-604F) 
supplemented with 10% heat-inactivated fetal bovine 
serum, or in K-SFM (RWPE-1; GIBCO; #17005-042), 
in a humidified incubator at 37°C with a supply of 5% 
CO2/95% air atmosphere. Cell lines are tested fortnightly 
for the absence of Mycoplasma and periodically (every 
six months) monitored for DNA profile of short tandem 
repeats analysis by the AmpFISTR Identifiler PCR 
amplification kit (Applied Biosystems; #4322288). All cell 
lines were last tested in September 2014.
Cell growth inhibition assay and drug 
interaction analysis
The antiproliferative activity of SINE, alone or in 
combination with YM155, was determined by the CellTiter 
96® AQueous One Solution Cell Proliferation Assay 
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(MTS; Promega; #G3580), as detailed in Supplementary 
Materials and Methods. Concentrations able to inhibit cell 
growth by 50% (IC50) and 80% (IC80) were determined 
graphically from the dose-response curves obtained after 
a 72-hour exposure of cells to SINE.
The nature of the interaction between YM155 and 
SINE was evaluated according to the method described 
by Chou and Talalay [45] using the CalcuSyn software 
(Biosoft). Specifically, combination index (CI) values 
<1 or >1 indicate synergy or antagonism, respectively, 
whereas a CI value of 1 indicates additivity. Such an 
interaction was also determined according to the method 
of Kern et al [46]. In brief, the expected cell survival 
(Sexp, defined as the product of the survival observed 
with selinexor alone and the survival observed with 
YM155 alone) and the observed cell survival (Sobs) with 
the selinexor/YM155 combination were used to construct 
an index (R)=Sexp/Sobs. R indexes >1 or <1 indicate 
synergism or antagonism, respectively, whereas R index 
of 1 indicates additivity.
Cell cycle distribution and apoptosis analysis
Both adherent and floating cells were fixed in 70% 
EtOH and incubated at 4°C for 30 min in staining solution 
containing 50 μg/mL of propidium iodide, 50 mg/mL of 
RNase, and 0.05% Nonidet-P40 in PBS. Samples were 
analyzed with a FACSCalibur cytofluorimeter (Becton 
Dickinson). At least 30,000 events were read, and 
histograms were analyzed using the CellQuest software 
according to the Modfit model (Becton Dickinson).
Apoptosis was detected by using FITC Annexin V 
Apoptosis Detection kit I (BD Pharmigen; #556547), as 
detailed in Supplementary Materials and Methods. In the 
same cellular samples, the catalytic activity of caspase-3 
was measured by means of the APOPCYTO/caspase-3 kit 
(MBL International; #4815). Briefly, cells were washed, 
pelleted, and lyzed according to the manufacturer’s 
instructions. Total protein and the specific fluorogenic 
substrate N-acetyl-Asp-Glu-Val-Asp-pNA (DEVD-pNA) 
were mixed for 1 hour at 37°C and transferred to 96-well 
microtiter plates. The hydrolysis of the specific substrates 
was monitored by a spectrofluorometer (POLARstar 
OPTIMA) with 380-nm excitation and 460-nm emission 
filters. Results were expressed as relative fluorescence 
units (rfu).
Protein extraction and western blot analysis
Nuclear and cytosolic fractions were obtained from 
DMPM cells using the nuclear/cytosol fractionation kit 
(MBL International; #JM-K266). For the assessment of 
the ubiquitinated form of survivin, nuclear extracts were 
immunoprecipitated with the anti-survivin antibody 
(Abcam Inc.; #ab469) for 16 hours at 4°C by addition 
of a 50:50 protein A slurry. Tumor protein lysates were 
obtained from frozen xenograft samples pulverized by the 
Mikro-Dismembrator II (B. Brown Biotech International).
The antibodies used in the study were CDKN1a 
(#ab7960), p53 (#ab26), ubiquitin (#ab7780), survivin 
(#ab469), β-actin (#ab8227), TBP (#ab818) (Abcam Inc.), 
STAT3 (#4904) and STAT3 Ac (#2523) (Cell Signaling 
Technology). Western blot analysis was carried out as 
detailed in Supplementary Material and Methods.
ELISA assay
Survivin protein was quantified in whole or nuclear/
cytosolic cell lysate obtained from cells exposed to SINE 
in the presence or absence of subtoxic concentrations of 
Bortezomib (1 nmol/L; Selleck Chemicals; #S1013) using 
Surveyor™ IC Human Total Survivin Immunoassay (R&D 
Systems; #SUV647) according to the manufacturer’s 
protocol.
Quantitative RT-PCR
Total RNA (0.5 μg) isolated from DMPM cells 
using Trizol reagent (Life Technologies; #15596-026) 
was reverse transcribed using the GeneAmp RNA PCR 
Core kit (Applied Biosystems; #N8080143) according to 
the manufacturer’s instructions. Quantification of survivin 
mRNA expression levels was assessed by quantitative RT-
PCR (qRT-PCR) as detailed in Supplementary Material 
and Methods.
In vivo experiments
In both DMPM models, treatment with KPT-SINE 
started 4 days after tumors injection (early-stage tumors) 
or when tumors were ~ 800 mm3 (late-stage tumors). 
Drugs were delivered by oral gavage according to different 
doses and schedule determined on the basis of preliminary 
experiments aimed at defining the most active/less toxic 
conditions (data not shown): KPT-251, 50 mg/kg twice 
a week for 4 weeks (q3-4d/w × 8); KPT-276, 50 mg/kg 
5 days a week for 3 weeks (5d/w × 3w); selinexor, 10 mg/kg 
q3-4d/w × 8. For combination experiments, four days 
after cell injection, mice (8 mice/group) were randomized 
to receive the drug vehicle or selinexor (p.o., 10 mg/kg, 
q3-4d/w × 8) and YM155 (s.c., 4 mg/kg, 5d/w × 4w), 
singly administered or in combination. Tumor growth was 
followed by biweekly measurements of tumor diameters 
with a Vernier calliper and tumor volume (TV) was 
calculated according to the formula: TV (mm3) = d2xD/2, 
where d and D are the shortest and the longest diameter, 
respectively. The anti-tumor activity was assessed as TV 
inhibition percentage (TVI%) in treated versus control 
mice, calculated as follows: TVI% = 100-(mean TV 
treated/mean TV control × 100).
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Orthotopic model was generated by injecting 
107 exponentially growing STO cells suspended in 200 μl 
saline in the peritoneum of SCID mice. The day after 
cell injection, mice were randomized (9 mice/group) to 
receive the drug vehicle or selinexor at 10 mg/kg by oral 
gavage q3-4d/w × 8. Twenty-five days after cell injection 
(i.e. 24 hours after the last drug treatment) mice were 
sacrificed and the tumor masses present in the peritoneum 
were removed and weighted. The tumor weight inhibition 
percentage (TWI%) was used to assess the anti-tumor 
activity of selinexor. Drug treatment toxicity was 
determined as body weight loss and lethal toxicity. Deaths 
occurring in treated mice before the death of the first 
control mouse were ascribed to toxic effects.
At the end of each experiment, tumor specimens 
were fixed in 10% buffered formalin for subsequent 
histological and immunohistochemical analysis or flash 
frozen in liquid nitrogen for biochemical analysis.
The origin of subcutaneous and orthotopic 
xenografts was authenticated through microsatellite 
analysis by the AmpFISTR Identifiler PCR Amplification 
Kit (Applied Biosystems).
Immunohistochemical analysis
Biogenex I6000 automated immunostainer was used 
to carry out immunohistochemical analyses on formalin-
fixed, paraffin-embedded tumors. Antigen was retrieved 
by steaming with Declere™ reagent (Cell Marque; 
#921P). Background was blocked with Power Block™ 
Universal Blocking Reagent (Biogenex; #BS-1310). 
Primary antibody against survivin (Abcam Inc.; #ab469) 
was applied for 1 hour at room temperature followed 
by detection with the two-step, HiDef Detection™ HRP 
Polymer System kit (Cell Marque; #954D), followed by 
DAB substrate (Cell Marque; #957D). Samples were 
counterstained with hematoxylin, dehydrated, cleared, and 
coverslipped.
The TUNEL Apoptosis Detection Kit (Millipore; 
#17-141) was used according to manufacturers’ protocol 
for the detection of the endonucleolytic cleavage of 
chromatin, characteristic of apoptosis.
Statistical analysis
Statistical evaluation of data was done with 
two-tailed Student’s t test. Ps < 0.05 were considered 
statistically significant.
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